Organogenesis Holdings Financials - Benzinga

Organogenesis Holdings Inc

ORGONASDAQ

Trade with Public

Trade with Public

$1.67

-0.13-7.22%

At close: Aug 24, 5:00 PM EST

$1.69

0.021.2%

After Hours: 5:35 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Organogenesis Holdings Financials

Organogenesis Holdings (ORGO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Organogenesis Hldgs Q2 Adj. EPS $(0.69) Misses $(0.35) Estimate, Sales $100.779M Beat $54.250M Estimate

Benzinga Newsdesk

PRO
Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est

Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.

Benzinga Newsdesk

PRO
Organogenesis Hldgs Q2 Sales $100.779M Beat $54.250M Estimate

Benzinga Newsdesk

PRO
Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est

Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.

Benzinga Newsdesk

PRO
Organogenesis Hldgs Q1 Adj. EPS $(0.34) Misses $(0.31) Estimate, Sales $36.250M Miss $43.300M Estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 209.09 percent decrease over losses of $(0.11) per share

Benzinga Newsdesk

PRO
Organogenesis Holdings Sees FY2026 Sales $350.000M-$420.000M vs $543.400M Est.

Organogenesis Holdings (NASDAQ:ORGO) sees FY2026 sales of $350.000 million-$420.000 million vs $543.400 million analyst estimate.

Benzinga Newsdesk